This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Freytag, S. O. Articles by Kim, J. H. Search for Related Content PubMed PubMed Citation Articles by Freytag, S. O. Articles by Kim, J. H.

Phase I Study of Replication-Competent Adenovirus-Mediated Double-Suicide Gene Therapy in Combination with Conventional-Dose Three-Dimensional Conformal Radiation Therapy for the Treatment of Newly Diagnosed, Intermediate- to High-Risk Prostate Cancer¹

Departments of Radiation Oncology [S. O. F., J. P., D. P., D. G. P., X. X., S. B., J. H. K.], Urology [H. S., J. P.], Pathology [M. D-V.], and Biostatistics [M. L.], Henry Ford Health System, Detroit, Michigan 48202

The primary study objective was to determine the safety of intraprostatic administration of a replication-competent, oncolytic adenovirus containing a cytosine deaminase (CD)/herpes simplex virus thymidine kinase (HSV-1 TK) fusion gene concomitant with increasing durations of 5-fluorocytosine and valganciclovir prodrug therapy and conventional-dose three-dimensional conformal radiation therapy (3D-CRT) in patients with newly diagnosed, intermediate- to high-risk prostate cancer. Secondary objectives were to determine the persistence of therapeutic transgene expression in the prostate and to examine early posttreatment response. Fifteen patients in five cohorts received a single intraprostatic injection of 10¹² viral particles of the replication-competent Ad5-CD/TKrep adenovirus on day 1. Two days later, patients were administered 5-fluorocytosine and valganciclovir prodrug therapy for 1 (cohorts 1–3), 2 (cohort 4), or 3 (cohort 5) weeks along with 70–74 Gy 3D-CRT. Sextant needle biopsy of the prostate was obtained at 2 (cohort 1), 3 (cohort 2), and 4 (cohort 3) weeks for determination of the persistence of transgene expression. There were no dose-limiting toxicities and no significant treatment-related adverse events. Ninety-four percent of the adverse events observed were mild to moderate and self-limiting. Acute urinary and gastrointestinal toxicities were similar to those expected for conventional-dose 3D-CRT. Therapeutic transgene expression was found to persist in the prostate for up to 3 weeks after the adenovirus injection. As expected for patients receiving definitive radiation therapy, all patients experienced significant declines in prostate-specific antigen (PSA). The mean PSA half-life in patients administered more than 1 week of prodrug therapy was significantly shorter than that of patients receiving prodrugs for only 1 week (0.6 versus 2.0 months; P < 0.02) and markedly shorter than that reported previously for patients treated with conventional-dose 3D-CRT alone (2.4 months). With a median follow-up of only 9 months, 5 of 10 (50%) patients not treated with androgen-deprivation therapy achieved a serum PSA 0.5 ng/ml. The results demonstrate that replication-competent adenovirus-mediated double-suicide gene therapy can be combined safely with conventional-dose 3D-CRT in patients with intermediate- to high-risk prostate cancer. The shorter than expected PSA half-life in patients receiving more than 1 week of prodrug therapy may suggest a possible interaction between the oncolytic adenovirus and/or double-suicide gene therapies and radiation therapy.

This article has been cited by other articles:

				T. Hakkarainen, M. Rajecki, M. Sarparanta, M. Tenhunen, A. J. Airaksinen, R. A. Desmond, K. Kairemo, and A. Hemminki Targeted Radiotherapy for Prostate Cancer with an Oncolytic Adenovirus Coding for Human Sodium Iodide Symporter Clin. Cancer Res., September 1, 2009; 15(17): 5396 - 5403. [Abstract] [Full Text] [PDF]

				M. Hingorani, C. L. White, A. Merron, I. Peerlinck, M. E. Gore, A. Slade, S. D. Scott, C. M. Nutting, H. S. Pandha, A. A. Melcher, et al. Inhibition of Repair of Radiation-Induced DNA Damage Enhances Gene Expression from Replication-Defective Adenoviral Vectors Cancer Res., December 1, 2008; 68(23): 9771 - 9778. [Abstract] [Full Text] [PDF]

				L. N. Kaliberova, D. L. Della Manna, V. Krendelchtchikova, M. E. Black, D. J. Buchsbaum, and S. A. Kaliberov Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene Mol. Cancer Ther., September 1, 2008; 7(9): 2845 - 2854. [Abstract] [Full Text] [PDF]

				C. Su, M. Na, J. Chen, X. Wang, Y. Liu, W. Wang, Q. Zhang, L. Li, J. Long, X. Liu, et al. Gene-Viral Cancer Therapy Using Dual-Regulated Oncolytic Adenovirus with Antiangiogenesis Gene for Increased Efficacy Mol. Cancer Res., April 1, 2008; 6(4): 568 - 575. [Abstract] [Full Text] [PDF]

				G. Ungerechts, C. Springfeld, M. E. Frenzke, J. Lampe, P. B. Johnston, W. B. Parker, E. J. Sorscher, and R. Cattaneo Lymphoma Chemovirotherapy: CD20-Targeted and Convertase-Armed Measles Virus Can Synergize with Fludarabine Cancer Res., November 15, 2007; 67(22): 10939 - 10947. [Abstract] [Full Text] [PDF]

				H. Zeng, Q. Wei, R. Huang, N. Chen, Q. Dong, Y. Yang, and Q. Zhou Recombinant Adenovirus Mediated Prostate-Specific Enzyme Pro-Drug Gene Therapy Regulated by Prostate-Specific Membrane Antigen (PSMA) Enhancer/Promoter J Androl, November 1, 2007; 28(6): 827 - 835. [Abstract] [Full Text] [PDF]

				N. Li, J. Zhou, D. Weng, C. Zhang, L. Li, B. Wang, Y. Song, Q. He, D. Lin, D. Chen, et al. Adjuvant Adenovirus-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Administration Improves Outcome of Liver Transplantation in Patients with Advanced Hepatocellular Carcinoma Clin. Cancer Res., October 1, 2007; 13(19): 5847 - 5854. [Abstract] [Full Text] [PDF]

				D. S. Shewach and T. S. Lawrence Antimetabolite Radiosensitizers J. Clin. Oncol., September 10, 2007; 25(26): 4043 - 4050. [Abstract] [Full Text] [PDF]

				S. J. Advani, R. R. Weichselbaum, and S. J. Chmura Enhancing Radiotherapy With Genetically Engineered Viruses J. Clin. Oncol., September 10, 2007; 25(26): 4090 - 4095. [Abstract] [Full Text] [PDF]

				D. Sarkar, I. V. Lebedeva, Z.-z. Su, E.-S. Park, L. Chatman, N. Vozhilla, P. Dent, D. T. Curiel, and P. B. Fisher Eradication of Therapy-Resistant Human Prostate Tumors Using a Cancer Terminator Virus Cancer Res., June 1, 2007; 67(11): 5434 - 5442. [Abstract] [Full Text] [PDF]

				F. He, L. Li, D. Kim, B. Wen, X. Deng, P. H. Gutin, C. C. Ling, and G. C. Li Adenovirus-Mediated Expression of a Dominant Negative Ku70 Fragment Radiosensitizes Human Tumor Cells under Aerobic and Hypoxic Conditions Cancer Res., January 15, 2007; 67(2): 634 - 642. [Abstract] [Full Text] [PDF]

				M. L. Ramnaraine, W. E. Mathews, J. M. Donohue, C. M. Lynch, M. J. Goblirsch, and D. R. Clohisy Osteoclasts Direct Bystander Killing of Bone Cancer. Cancer Res., November 15, 2006; 66(22): 10929 - 10935. [Abstract] [Full Text] [PDF]

				M. Goblirsch, P. Zwolak, M. L. Ramnaraine, W. Pan, C. Lynch, P. Alaei, and D. R. Clohisy Novel Cytosine deaminase fusion gene enhances the effect of radiation on breast cancer in bone by reducing tumor burden, osteolysis, and skeletal fracture. Clin. Cancer Res., May 15, 2006; 12(10): 3168 - 3176. [Abstract] [Full Text] [PDF]

				C. Jogler, D. Hoffmann, D. Theegarten, T. Grunwald, K. Uberla, and O. Wildner Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species. J. Virol., April 1, 2006; 80(7): 3549 - 3558. [Abstract] [Full Text] [PDF]

				P. D. Boucher, M. M. Im, S. O. Freytag, and D. S. Shewach A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy. Cancer Res., March 15, 2006; 66(6): 3230 - 3237. [Abstract] [Full Text] [PDF]

				J. Zhou, Q. Gao, G. Chen, X. Huang, Y. Lu, K. Li, D. Xie, L. Zhuang, J. Deng, and D. Ma Novel Oncolytic Adenovirus Selectively Targets Tumor-Associated Polo-Like Kinase 1 and Tumor Cell Viability Clin. Cancer Res., December 1, 2005; 11(23): 8431 - 8440. [Abstract] [Full Text] [PDF]

				H. Fukuhara, R. L. Martuza, S. D. Rabkin, Y. Ito, and T. Todo Oncolytic Herpes Simplex Virus Vector G47{Delta} in Combination with Androgen Ablation for the Treatment of Human Prostate Adenocarcinoma Clin. Cancer Res., November 1, 2005; 11(21): 7886 - 7890. [Abstract] [Full Text] [PDF]

				S. Li, B. Yu, P. An, G. Chen, W. Lu, H. Cai, W. Guo, and F. Zuo Combined Liposome-Mediated Cytosine Deaminase Gene Therapy with Radiation in Killing Rectal Cancer Cells and Xenografts in Athymic Mice Clin. Cancer Res., May 1, 2005; 11(9): 3574 - 3578. [Abstract] [Full Text] [PDF]

				E. Mitrofanova, R. Unfer, N. Vahanian, W. Daniels, E. Roberson, T. Seregina, P. Seth, and C. Link Jr. Rat Sodium Iodide Symporter for Radioiodide Therapy of Cancer Clin. Cancer Res., October 15, 2004; 10(20): 6969 - 6976. [Abstract] [Full Text] [PDF]

				R. L. Chu, D. E. Post, F. R. Khuri, and E. G. Van Meir Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5299 - 5312. [Abstract] [Full Text] [PDF]

				E. A. Sausville Genes in the Service of Therapeutic Index: Progress for Virus-Directed Enzyme Prodrug Therapy J. Clin. Oncol., May 1, 2004; 22(9): 1535 - 1537. [Full Text] [PDF]